secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2025-02-25T23:59:59+00:00
Accession:  0001787306-25-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q4 ZORYVE revenue $69.4M (+413% YoY); net loss narrows to $10.8M
------------------------------------------------------------------------

- Q4 total revenue $71.4M vs $13.5M YoY; net loss $0.09/share vs $0.72/share prior year.
- Full-year ZORYVE net product revenue $166.5M (+471% YoY); ZORYVE is #1 branded non-steroidal topical in U.S.
- Submitted sNDA for ZORYVE cream 0.05% for atopic dermatitis in children ages 2-5; target action Q4 2025.
- Prepaid $100M of $200M term loan; maintains ability to re-draw; cash & securities $228.6M at year-end.
- ZORYVE foam for scalp/body psoriasis PDUFA date May 22, 2025; partnered with Odell Beckham Jr. for seborrheic dermatitis awareness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/0001787306-25-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730625000028/arqt-20250225.htm
  HTML page:      https://secwatch.observer/filing/0001787306-25-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer